What happened. Shares of CRISPR Therapeutics (NASDAQ:CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.8 Jan 2022
What is the best Crispr stock?
Company Market Cap
----------------------------------- ------------
CRISPR Therapeutics (NASDAQ:CRSP) $6.1 billion
Editas Medicine (NASDAQ:EDIT) $1.9 billion
Intellia Therapeutics (NASDAQ:NTLA) $8.9 billion
Verve Therapeutics (NASDAQ:VERV) $1.9 billion
Why is CRSP stock dropping?
Shares of CRISPR Therapeutics (NASDAQ:CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.8 Jan 2022
Is CRSP overpriced?
The stock of CRISPR Therapeutics AG (NAS:CRSP, 30-year Financials) gives every indication of being significantly overvalued, according to GuruFocus Value calculation. At its current price of $131.88 per share and the market cap of $10 billion, CRISPR Therapeutics AG stock is estimated to be significantly overvalued.29 Apr 2021